BioNTech SE (BNTX)

NASDAQ: BNTX · IEX Real-Time Price · USD
+1.87 (1.34%)
Jun 29, 2022 12:46 PM EDT - Market open
Market Cap 34.43B
Revenue (ttm) 25.61B
Net Income (ttm) 14.14B
Shares Out 243.02M
EPS (ttm) 55.75
PE Ratio 2.54
Forward PE 3.10
Dividend $2.13 (1.50%)
Ex-Dividend Date Jun 2, 2022
Volume 687,675
Open 139.64
Previous Close 139.82
Day's Range 137.01 - 143.25
52-Week Range 117.08 - 464.00
Beta -0.29
Analysts Buy
Price Target 257.83 (+82.0%)
Earnings Date Aug 8, 2022

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, ... [Read more...]

Industry Biotechnology
IPO Date Oct 10, 2019
Employees 3,082
Stock Exchange NASDAQ
Ticker Symbol BNTX
Full Company Profile

Financial Performance

In 2021, BioNTech SE's revenue was 18.98 billion, an increase of 3,834.63% compared to the previous year's 482.30 million. Earnings were 10.29 billion, an increase of 67,613.82%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is 257.83, which is an increase of 81.97% from the latest price.

Price Target
(81.97% upside)
Analyst Consensus: Buy
Stock Forecasts


FDA recommends updating COVID booster shots to fight Omicron

Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.

Other symbols: JNJMRNAPFE

FDA Panel Recommends Modifying COVID Jabs to Target Omicron

The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.

Other symbols: MRNAPFE

FDA advisers recommend Covid fall boosters

CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA advisers recommendation for covid fall boosters.

Other symbols: MRNAPFE

Why BioNTech Stock Rose Today

Its latest COVID-19 vaccine appears to be effective against the most common viral variants.

Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response. The companies said that 30 µg and 60 µg doses ...

Other symbols: PFE

7 Biotech Stocks With Key Catalysts Coming in July

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on Inves...

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omi...

NEW YORK and MAINZ, GERMANY, JUNE 25, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-a...

BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate ...

MAINZ, Germany, June 23, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRI...

BioNTech breaks ground on first mRNA manufacturing facility in Africa in Kigali, Rwanda

BioNTech SE BNTX, +0.33% said Thursday it has broken ground on the construction of the first mRNA manufacturing facility in Africa, a plant in Kigali, Rwanda that is expected to employ about 100 workers...

BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa

MAINZ, Germany and KIGALI, Rwanda, June 23, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech”) has reached the next milestone in the establishment of scalable mRNA vaccine production in Afri...

Got $5,000? These 2 Growth Stocks Are Absurdly Cheap Buys

You'll get a lot of bang for your buck with these stocks.

Other symbols: AMZN

COVID-19 vaccines slowly begin to roll out for young kids

Yahoo Finance's Anjalee Khemlani discusses the rollout of COVID vaccines for kids 6 months to 5 years, plus a new test that could indicate when a person needs a booster shot.

Other symbols: JNJMRNAPFE

FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids

FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.

Other symbols: MRNAPFE

BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations

MAINZ, Germany, June 20, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the "Company”) will host the first edition of the Company's Innovation Series on Wednesday, June 29th, 2022. Th...

7 Long-Term Stocks to Buy in a Bear Market

These long-term stocks to buy are from defensive sectors, because now is the time to play defense in your stock investing. The post 7 Long-Term Stocks to Buy in a Bear Market appeared first on InvestorP...


Covid-19 Vaccinations For Children Starting At Age 6 Months Approved By CDC

Despite continued skepticism from parents and some scientific advisers, the Centers for Disease Control and Prevention on Saturday recommended Covid-19 vaccines for children as young as 6 months. The ru...

Other symbols: MRNAPFE

CDC Advisers Recommend COVID Vaccines for Kids as Young as 6 Months Old

Very young children may be able to start receiving shots early next week.

Other symbols: MRNAPFE

CDC panel recommends COVID-19 vaccine for children as young as 6 months old

"We've taken a major step forward today," said Dr. Oliver Brooks, one of the members of the advisory panel.

Other symbols: MRNAPFE

CDC advisers recommend COVID-19 shots for children under 5

U.S. health advisers on Saturday recommended COVID-19 vaccines for infants, toddlers and preschoolers — the last group without the shots.

Other symbols: MRNAPFE

CDC Panel Recommends Covid Vaccines For Young Children

Shots are expected to start going in arms next week.

Other symbols: MRNAPFE

CDC advisors recommend Covid vaccines for children as young as 6 months

The CDC committee voted unanimously to recommend the shots for use in infants through preschoolers after two days of meetings that were open to the public.

Other symbols: MRNAPFE

FDA Authorizes Covid Vaccine for Kids 5 and Under

Covid-19 vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from US regulators, meaning almost all the American population can soon get pandemic protection. ...

Other symbols: MRNAPFE

Moderna, Pfizer stocks edge higher after FDA authorizes COVID vaccines for kids

Yahoo Finance Live's Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.

Other symbols: MRNAPFE

FDA Approves COVID Vaccines for Kids as Young as 6 Months Old

Pending the CDC's signoff, both Moderna and Pfizer shots could be available for the youngest children within days.

Other symbols: MRNAPFE

FDA clears Pfizer, Moderna Covid vaccines for young children

The U.S. FDA has authorized Moderna's and Pfizer's Covid-19 vaccines for kids as young as 6 months. CNBC's Meg Tirrell joins 'Squawk on the Street' with the details.

Other symbols: MRNAPFE